NCT00111553View on ClinicalTrials.gov

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

August 31, 2006

Conditions
Leishmaniasis, Cutaneous
Interventions
BIOLOGICAL

Leish-111f + MPL-SE vaccine

Trial Locations (2)

31270-901

Universidade Federal de Minas Gerais, Belo Horizonte

39480-000

Ambulatório de Leishmanioses da Secretaria Municipal da Saude de Januária, Januária

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Access to Advanced Health Institute (AAHI)

OTHER

NCT00111553 - Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis | Biotech Hunter | Biotech Hunter